Featured Story

Cinven snatches up Synlab for $1.96B to beef up in diagnostics

European private equity firm Cinven is snatching up German medical lab operator Synlab for €1.75 billion ($1.96 billion), continuing its dealmaking streak weeks after it announced it would shell out $1.3 billion for French diagnostics outfit Labco.

Google and the Broad Institute join forces for genomic data sharing

Google is teaming up with The Broad Institute of MIT and Harvard to create new ways of sharing genomic data and reduce barriers associated with storing and processing genetic information.

Broad Institute bags $20M for drug-resistant TB research

As the drug-resistant tuberculosis epidemic rages on, The Broad Institute of MIT and Harvard got a $20 million gift to develop new diagnostic and therapeutic approaches for the disease. Bill Ackman, CEO of Pershing Square, and Seth Klarman, president of The Baupost Group, rallied more than 20 investors to raise the funds.

Qiagen to partner with Japan's Hitachi on molecular testing

Qiagen will combine its expertise in assays and biomarker panels with Hitachi's knowledge of instrumentation and manufacturing to advance research-based and clinical molecular testing via a strategic collaboration.

Advanced Cell Diagnostics receives $22M to develop its RNA biomarker tech

Silicon Valley's Advanced Cell Diagnostics recently announced that it has raised $22 million in a Series C financing led by Summit Partners, with participation from Kenson Ventures. Previous investors in the round were Morningside Ventures and New Leaf Venture Partners.


From Our Sister Sites


Allergan Chairman Paul Bisaro has been quick to cut what he sees as redundant operations and people to help pay for his aggressive buying. Now, he has set his sights on the company's ancestry, with plans to whack a plant, and 300 jobs, in Iceland. 


The U.S. Food and Drug Administration cleared the FlowTriever catheter-based thrombectomy device in March. Now its maker, Inari Medical, has garnered a $12.4 million Series B round to continue to improve the product, which is designed to extract significant amounts of clot from large blood vessels, and to demonstrate its value in clinical testing.